[go: up one dir, main page]

MX2018001989A - Formulaciones farmaceuticas. - Google Patents

Formulaciones farmaceuticas.

Info

Publication number
MX2018001989A
MX2018001989A MX2018001989A MX2018001989A MX2018001989A MX 2018001989 A MX2018001989 A MX 2018001989A MX 2018001989 A MX2018001989 A MX 2018001989A MX 2018001989 A MX2018001989 A MX 2018001989A MX 2018001989 A MX2018001989 A MX 2018001989A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
ascomycin
pulmonary hypertension
prodrug
solvate
Prior art date
Application number
MX2018001989A
Other languages
English (en)
Inventor
Gu Leo
S Banait Narinder
Original Assignee
Vivus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivus Inc filed Critical Vivus Inc
Publication of MX2018001989A publication Critical patent/MX2018001989A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona composiciones y métodos para el tratamiento o prevención de hipertensión pulmonar que comprenden administrar una ascomicina, o una sal, solvato, análogo o profármaco farmacéuticamente aceptable de la misma al paciente con hipertensión pulmonar. Se describen en la presente formulaciones líquidas que suministran una ascomicina. La formulación líquida se puede colocar en una cápsula de gelatina blanda.
MX2018001989A 2015-08-19 2016-08-16 Formulaciones farmaceuticas. MX2018001989A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562207324P 2015-08-19 2015-08-19
PCT/US2016/047148 WO2017031105A1 (en) 2015-08-19 2016-08-16 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
MX2018001989A true MX2018001989A (es) 2018-06-19

Family

ID=58051644

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018001989A MX2018001989A (es) 2015-08-19 2016-08-16 Formulaciones farmaceuticas.
MX2022013450A MX2022013450A (es) 2015-08-19 2018-02-15 Formulaciones farmaceuticas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022013450A MX2022013450A (es) 2015-08-19 2018-02-15 Formulaciones farmaceuticas.

Country Status (6)

Country Link
US (5) US20180243224A1 (es)
EP (2) EP3337463A4 (es)
KR (1) KR102706357B1 (es)
AU (2) AU2016308568A1 (es)
MX (2) MX2018001989A (es)
WO (1) WO2017031105A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180325891A1 (en) * 2017-05-10 2018-11-15 Corcept Therapeutics, Inc. Octahydro azadecalin formulations
KR20200134271A (ko) * 2018-03-19 2020-12-01 제미니 라보라토리스, 엘엘씨 면역억제성 투약형 및 사용 방법
WO2020239086A1 (en) 2019-05-31 2020-12-03 Medical And Pharmaceutical Industry Technology And Development Center Oral composition and methods for manufacturing the same and treatment
US11185513B1 (en) * 2021-05-07 2021-11-30 King Abdulaziz University Transfersome-containing transdermal film formulations and methods of use
CN116785244A (zh) * 2023-06-29 2023-09-22 上海众强药业有限公司 含司来帕格的固体分散体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR900506A (fr) 1943-12-10 1945-07-02 Oerlikon Buehrle Ag Culasse pour armes à feu à canon coulissant et à chargement par le recul
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
US6204243B1 (en) * 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
ATE398448T1 (de) * 1993-09-28 2008-07-15 Scherer Gmbh R P Herstellung von weichgelatinekapseln
TW450810B (en) 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
EP1663217B1 (en) * 2003-08-29 2010-07-07 LifeCycle Pharma A/S Solid dispersions comprising tacrolimus
KR100678829B1 (ko) * 2004-12-06 2007-02-05 한미약품 주식회사 타크로리무스의 경구용 마이크로에멀젼 조성물
ITMI20070720A1 (it) * 2007-04-06 2008-10-07 Monteresearch Srl Composizioni orali contenenti tacrolimus in forma amorfa
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability

Also Published As

Publication number Publication date
US20260021051A1 (en) 2026-01-22
KR102706357B1 (ko) 2024-09-11
US20210113477A1 (en) 2021-04-22
AU2016308568A1 (en) 2018-02-22
US20190350864A1 (en) 2019-11-21
CA2994859A1 (en) 2017-02-23
KR20180041704A (ko) 2018-04-24
EP3337463A1 (en) 2018-06-27
US20180243224A1 (en) 2018-08-30
MX2022013450A (es) 2022-11-16
US20210401759A1 (en) 2021-12-30
AU2022201340A1 (en) 2022-03-24
EP3337463A4 (en) 2019-04-03
EP4066822A1 (en) 2022-10-05
WO2017031105A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
MX2016011468A (es) Inhibidores de calicreína plasmática humana.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2018001989A (es) Formulaciones farmaceuticas.
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
BR112015023481A2 (pt) composição de lipossoma de liberação controlada de fármaco
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
BR112017009510A2 (pt) composições compreendendo ciclosporina
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
MX2021000127A (es) Formulaciones de un inhibidor de axl/mer.
MX2019001577A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
PT3215143T (pt) Combinação compreendendo espirulina e palmitoíletanolamida
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
MX2017014301A (es) Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.
MX2017001649A (es) Peptido derivado de koc1 y vacuna que lo incluye.
MX2020005869A (es) Derivados de imidazopiridina y su uso como medicamento.